The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
A Study to Evaluate Safety and Efficacy of Mepolizumab in Patients with Moderate Persistent Asthma
Abstract
RATIONALE: Accumulation of eosinophils in the bronchial mucosa of individuals with asthma is considered to be a central event in the pathogenesis of asthma. In animal models, airway eosinophil recruitment and airway hyperresponsiveness in response to allergen challenge are reduced by specific targeting of interleukin-5. A previous small dose-finding study found that mepolizumab, a humanized anti-interleukin-5 monoclonal antibody, had no effect on allergen challenge in humans. OBJECTIVES: To investigate the effect of three intravenous infusions of mepolizumab, 250 or 750 mg at monthly intervals, on clinical outcome measures in 362 patients with asthma experiencing persistent symptoms despite inhaled corticosteroid therapy (400-1,000 mug of beclomethasone or equivalent). METHODS: Multicenter, randomized, double-blind, placebo-controlled study. MEASUREMENTS AND MAIN RESULTS: Morning peak expiratory flow, forced expiratory volume in 1 second, daily beta(2)-agonist use, symptom scores, exacerbation rates, and quality of life measures. Sputum eosinophil levels were also measured in a subgroup of 37 individuals. Mepolizumab was associated with a significant reduction in blood and sputum eosinophils in both treatment groups (blood, P < 0.001 for both doses; sputum, P = 0.006 for 250 mg and P = 0.004 for 750 mg). There were no statistically significant changes in any of the clinical end points measured. There was a nonsignificant trend for decrease in exacerbation rates in the mepolizumab 750-mg treatment group (P = 0.065). CONCLUSIONS: Mepolizumab treatment does not appear to add significant clinical benefit in patients with asthma with persistent symptoms despite inhaled corticosteroid therapy. Further studies are needed to investigate the effect of mepolizumab on exacerbation rates, using protocols specifically tailored to patients with asthma with persistent airway eosinophilia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Predominant TH2-like Bronchoalveolar T-Lymphocyte Population in Atopic Asthma
Robinson, D. S., Hamid, Q., Ying, S., Tsicopoulos, A., Barkans, J., Bentley, A. M., Corrigan, C., Durham, S. R., & Kay, A. B. (1992) · New England Journal of Medicine · doi:10.1056/nejm199201303260504 · Cited by 2,768
Self-citationEosinophilic Inflammation in Asthma
Bousquet, J., Chanez, P., Lacoste, J. Y., Barnéon, G., Ghavanian, N., Enander, I., Venge, P., Ahlstedt, S., Simony-Lafontaine, J., Godard, P., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199010113231505 · Cited by 2,499
Leckie, M. J., Brinke, A. T., Khan, J., Diamant, Z., O'Connor, B. J., Walls, C. M., Mathur, A. K., Cowley, H. C., Chung, K. F., Djukanovic, R., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03496-6 · Cited by 1,814
Self-citationAsthma exacerbations and sputum eosinophil counts: a randomised controlled trial
Green, R. H., Brightling, C. E., McKenna, S., Hargadon, B., Parker, D., Bradding, P., Wardlaw, A. J., & Pavord, I. D. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11679-5 · Cited by 1,755
Foster, P. S., Hogan, S. P., Ramsay, A. J., Matthaei, K. I., & Young, I. G. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.1.195 · Cited by 1,370
WENZEL, S. E., SCHWARTZ, L. B., LANGMACK, E. L., HALLIDAY, J. L., TRUDEAU, J. B., GIBBS, R. L., & CHU, H. W. (1999) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.160.3.9812110 · Cited by 1,235
Self-citationGreen, R. H. (2002) · Thorax · doi:10.1136/thorax.57.10.875 · Cited by 848
Flood-Page, P., Menzies-Gow, A., Phipps, S., Ying, S., Wangoo, A., Ludwig, M. S., Barnes, N., Robinson, D., & Kay, A. B. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17974 · Cited by 841
Self-citationExpression of mRNA for interleukin-5 in mucosal bronchial biopsies from asthma.
Hamid, Q., Azzawi, M., Ying, S., Moqbel, R., Wardlaw, A. J., Corrigan, C. J., Bradley, B., Durham, S. R., Collins, J. V., & Jeffery, P. K. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115166 · Cited by 833
Cited by
International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma
Chung, K. F., Wenzel, S. E., Brozek, J. L., Bush, A., Castro, M., Sterk, P. J., Adcock, I. M., Bateman, E. D., Bel, E. H., Bleecker, E. R., et al. (2014) · European Respiratory Journal · doi:10.1183/09031936.00202013 · Cited by 3,926
“While the anti-IL5 antibody, mepolizumab, was not beneficial in unselected adult patients with moderate asthma [321], when studied in severe asthma patients with persistent sputum”
BackgroundSelf-citationAsthma phenotypes: the evolution from clinical to molecular approaches
Wenzel, S. E. (2012) · Nature Medicine · doi:10.1038/nm.2678 · Cited by 2,412
Self-citationMepolizumab Treatment in Patients with Severe Eosinophilic Asthma
Ortega, H. G., Liu, M. C., Pavord, I. D., Brusselle, G. G., FitzGerald, J. M., Chetta, A., Humbert, M., Katz, L. E., Keene, O. N., Yancey, S. W., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1403290 · Cited by 2,322
Pavord, I. D., Korn, S., Howarth, P., Bleecker, E. R., Buhl, R., Keene, O. N., Ortega, H., & Chanez, P. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60988-x · Cited by 2,221
Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma
Haldar, P., Brightling, C. E., Hargadon, B., Gupta, S., Monteiro, W., Sousa, A., Marshall, R. P., Bradding, P., Green, R. H., Wardlaw, A. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808991 · Cited by 1,871
T-helper Type 2–driven Inflammation Defines Major Subphenotypes of Asthma
Woodruff, P. G., Modrek, B., Choy, D. F., Jia, G., Abbas, A. R., Ellwanger, A., Arron, J. R., Koth, L. L., & Fahy, J. V. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200903-0392oc · Cited by 1,803
Type 2 inflammation in asthma — present in most, absent in many
Fahy, J. V. (2015) · Nature Reviews Immunology · doi:10.1038/nri3786 · Cited by 1,654
Immunology of asthma and chronic obstructive pulmonary disease
Barnes, P. J. (2008) · Nature Reviews Immunology · doi:10.1038/nri2254 · Cited by 1,399
FitzGerald, J. M., Bleecker, E. R., Nair, P., Korn, S., Ohta, K., Lommatzsch, M., Ferguson, G. T., Busse, W. W., Barker, P., Sproule, S., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31322-8 · Cited by 1,397
Self-citationMepolizumab for Prednisone-Dependent Asthma with Sputum Eosinophilia
Nair, P., Pizzichini, M. M. M., Kjarsgaard, M., Inman, M. D., Efthimiadis, A., Pizzichini, E., Hargreave, F. E., & O'Byrne, P. M. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805435 · Cited by 1,356
After asthma: redefining airways diseases
Pavord, I. D., Beasley, R., Agusti, A., Anderson, G. P., Bel, E., Brusselle, G., Cullinan, P., Custovic, A., Ducharme, F. M., Fahy, J. V., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)30879-6 · Cited by 1,073
Self-citationEosinophils: changing perspectives in health and disease
Rosenberg, H. F., Dyer, K. D., & Foster, P. S. (2013) · Nature Reviews Immunology · doi:10.1038/nri3341 · Cited by 989
The cytokine network in asthma and chronic obstructive pulmonary disease
Barnes, P. J. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36130 · Cited by 982
Interleukins, from 1 to 37, and interferon-γ: Receptors, functions, and roles in diseases
Akdis, M., Burgler, S., Crameri, R., Eiwegger, T., Fujita, H., Gomez, E., Klunker, S., Meyer, N., O’Mahony, L., Palomares, O., et al. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.11.050 · Cited by 778
Targeting key proximal drivers of type 2 inflammation in disease
Gandhi, N. A., Bennett, B. L., Graham, N. M. H., Pirozzi, G., Stahl, N., & Yancopoulos, G. D. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd4624 · Cited by 766
Reslizumab for Poorly Controlled, Eosinophilic Asthma: A Randomized, Placebo-controlled Study
Castro, M., Mathur, S., Hargreave, F., Boulet, L.-P., Xie, F., Young, J., Wilkins, H. J., Henkel, T., & Nair, P. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201103-0396oc · Cited by 716
Treatment strategies for allergy and asthma
Holgate, S. T., & Polosa, R. (2008) · Nature Reviews Immunology · doi:10.1038/nri2262 · Cited by 691
Mepolizumab, a humanized anti–IL-5 mAb, as a treatment option for severe nasal polyposis
Gevaert, P., Van Bruaene, N., Cattaert, T., Van Steen, K., Van Zele, T., Acke, F., De Ruyck, N., Blomme, K., Sousa, A. R., Marshall, R. P., et al. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.07.056 · Cited by 629
Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients
Jia, G., Erickson, R. W., Choy, D. F., Mosesova, S., Wu, L. C., Solberg, O. D., Shikotra, A., Carter, R., Audusseau, S., Hamid, Q., et al. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.06.025 · Cited by 615
König, I. R., Fuchs, O., Hansen, G., von Mutius, E., & Kopp, M. V. (2017) · European Respiratory Journal · doi:10.1183/13993003.00391-2017 · Cited by 572
Castro, M., Wenzel, S. E., Bleecker, E. R., Pizzichini, E., Kuna, P., Busse, W. W., Gossage, D. L., Ward, C. K., Wu, Y., Wang, B., et al. (2014) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(14)70201-2 · Cited by 488
Self-citationA sensory neuronal ion channel essential for airway inflammation and hyperreactivity in asthma
Caceres, A. I., Brackmann, M., Elia, M. D., Bessac, B. F., del Camino, D., D'Amours, M., Witek, J. S., Fanger, C. M., Chong, J. A., Hayward, N. J., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900591106 · Cited by 463
Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels
Bjermer, L., Lemiere, C., Maspero, J., Weiss, S., Zangrilli, J., & Germinaro, M. (2016) · Chest · doi:10.1016/j.chest.2016.03.032 · Cited by 426
IL-5- and eosinophil-mediated inflammation: from discovery to therapy
Kouro, T., & Takatsu, K. (2009) · International Immunology · doi:10.1093/intimm/dxp102 · Cited by 422
Targeting cytokines to treat asthma and chronic obstructive pulmonary disease
Barnes, P. J. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0006-6 · Cited by 418
Fajt, M. L., & Wenzel, S. E. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.12.1871 · Cited by 353
Self-citationEosinophilic airway inflammation: role in asthma and chronic obstructive pulmonary disease
George, L., & Brightling, C. E. (2016) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622315609251 · Cited by 326
Takatsu, K., & Nakajima, H. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.04.001 · Cited by 320
McDonald, V. M., Fingleton, J., Agusti, A., Hiles, S. A., Clark, V. L., Holland, A. E., Marks, G. B., Bardin, P. P., Beasley, R., Pavord, I. D., et al. (2019) · European Respiratory Journal · doi:10.1183/13993003.02058-2018 · Cited by 317
Farne, H. A., Wilson, A., Powell, C., Bax, L., & Milan, S. J. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010834.pub3 · Cited by 315
Ikutani, M., Yanagibashi, T., Ogasawara, M., Tsuneyama, K., Yamamoto, S., Hattori, Y., Kouro, T., Itakura, A., Nagai, Y., Takaki, S., et al. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1101270 · Cited by 314
Interleukin-5 and IL-5 receptor in health and diseases
TAKATSU, K. (2011) · Proceedings of the Japan Academy, Series B · doi:10.2183/pjab.87.463 · Cited by 297
Muraro, A., Lemanske, R. F., Hellings, P. W., Akdis, C. A., Bieber, T., Casale, T. B., Jutel, M., Ong, P. Y., Poulsen, L. K., Schmid-Grendelmeier, P., et al. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.03.010 · Cited by 284
Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome
Kim, S., Marigowda, G., Oren, E., Israel, E., & Wechsler, M. E. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.03.028 · Cited by 280
Holloway, J. W., Yang, I. A., & Holgate, S. T. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.10.071 · Cited by 266
Jacobsen, E. A., Ochkur, S. I., Pero, R. S., Taranova, A. G., Protheroe, C. A., Colbert, D. C., Lee, N. A., & Lee, J. J. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20071840 · Cited by 263
Targeting the interleukin pathway in the treatment of asthma
Chung, K. F. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00157-9 · Cited by 261
Asthma: pathogenesis and novel drugs for treatment
Olin, J. T., & Wechsler, M. E. (2014) · BMJ · doi:10.1136/bmj.g5517 · Cited by 256
Severe asthma: Advances in current management and future therapy
Barnes, P. J. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.11.006 · Cited by 174
Novel Biologicals for the Treatment of Allergic Diseases and Asthma
Tan, H.-T. T., Sugita, K., & Akdis, C. A. (2016) · Current Allergy and Asthma Reports · doi:10.1007/s11882-016-0650-5 · Cited by 68
Metadata
- Authors
- Flood-Page, P., Swenson, C., Faiferman, I., Matthews, J., Williams, M., Brannick, L., Robinson, D., Wenzel, S., Busse, W., Hansel, T. T., Barnes, N. C., & on behalf of the International Mepolizumab Study Group
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-12-01
- Volume
- 176
- Issue
- 11
- Pages
- 1062-1071
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- OpenAlex
- W1994585625
- Cited by
- 750
- References
- 35
- FWCI
- 23.14
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.